<DOC>
	<DOCNO>NCT02649426</DOCNO>
	<brief_summary>RADIANCE-HTN randomize , double-blind , sham control , 2-cohort study ( TRIO SOLO ) design demonstrate efficacy document safety Paradise Renal Denervation System two distinct population hypertensive subject .</brief_summary>
	<brief_title>A Study ReCor Medical Paradise System Clinical Hypertension</brief_title>
	<detailed_description>Subjects essential hypertension control 1 2 antihypertensive medication uncontrolled 0-2 antihypertensive medication include RADIANCE Solo cohort subject treatment resistant hypertension minimum 3 antihypertensive medication include RADIANCE Trio cohort . Prior randomization , subject hypertensive absence hypertension medication ( SOLO ) despite presence stabilize , single pill , triple , fix dose antihypertensive medication regimen ( TRIO ) .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Vascular Diseases</mesh_term>
	<criteria>TRIO SOLO Appropriately sign date informed consent Age ≥18 ≤75 year time consent Documented history essential hypertension SOLO Cohort : Either average seat office BP &lt; 180/110 mmHg screen visit stable regimen 1 2 antihypertensive medication least 4 week prior consent average seat office BP ≥ 140/90 mmHg &lt; 180/110 mmHg despite lifestyle measure antihypertensive medication TRIO Cohort : Average seat office BP ≥ 140/90 mmHg screen visit stable regimen least 3 antihypertensive medication different class include diuretic least 4 week prior consent Documented daytime ABP ≥ 135/85 mmHg &lt; 170/105 mmHg 4week washout/runin period ( SOLO cohort ) 4week stabilization period ( TRIO cohort ) Suitable renal anatomy compatible renal denervation procedure document renal CTA MRA good quality perform within one year prior consent ( CTA MRA obtain patient without recent ( ≤1 year ) renal image ) Able willing comply study procedure Solo Renal artery anatomy either side , ineligible treatment include : Main renal artery diameter &lt; 4 mm &gt; 8 mm Main renal artery length &lt; 25 mm A single functioning kidney Presence abnormal kidney ( secrete adrenal ) tumor Renal artery aneurysm Preexisting renal stent history renal artery angioplasty Prior renal denervation procedure Fibromuscular disease renal artery Presence renal artery stenosis origin ≥ 30 % Accessory artery diameter ≥ 2mm &lt; 4 mm &gt; 8 mm* Evidence active infection within 7 day procedure Iliac/femoral artery stenosis preclude insertion Paradise Catheter Type I diabetes mellitus uncontrolled Type II diabetes ( define plasma Hb1Ac ≥ 9.0 % ) Documented history chronic active inflammatory bowel disorder Chrohn 's disease ulcerative colitis eGFR &lt; 40 mL/min/1.73 m2 ( Modification Diet Renal Disease formula ) Brachial circumference ≥ 42 cm Any history cerebrovascular event ( e.g . stroke , transient ischemic event , cerebrovascular accident ) Any history severe cardiovascular event ( myocardial infarction , CABG , acute heart failure require hospitalization ( NYHA IIIIV ) Documented confirmed episode ( ) stable unstable angina Documented repeat ( &gt; 1 ) hospitalization hypertensive crisis within prior 12 month Prescribed standard antihypertensive cardiovascular medication ( e.g . beta blocker ) chronic condition ( e.g . ischemic heart disease ) discontinuation might pose serious risk health Documented history persistent permanent atrial tachyarrhythmia Active implantable medical device ( e.g . ICD CRTD ; neuromodulator/spinal stimulator ; baroreflex stimulator ) Chronic oxygen support mechanical ventilation nocturnal respiratory support sleep apnea . Primary pulmonary hypertension Documented contraindication allergy contrast medium amenable treatment Limited life expectancy &lt; 1 year discretion Investigator Any known , unresolved history drug use alcohol dependency , lack ability comprehend follow instruction , reason opinion investigator , would unlikely unable comply study protocol requirement whose participation may result data analysis confounders ( e.g . night shift worker ) Pregnant , nurse plan become pregnant ( negative pregnancy test require , document within maximum 7 day prior procedure woman child bear potential . Documentation effective contraception also required woman child bear potential ) Concurrent enrollment investigational drug device trial ( participation noninterventional Registries acceptable ) TRIO Exclusion Criteria Renal artery anatomy either side , ineligible treatment include : Main renal artery diameter &lt; 4 mm &gt; 8 mm Main renal artery length &lt; 25 mm A single functioning kidney Presence abnormal kidney ( secrete adrenal ) tumor Renal artery aneurysm Preexisting renal stent history renal artery angioplasty Prior renal denervation procedure Fibromuscular disease renal artery Presence renal artery stenosis origin ≥ 30 % Accessory artery diameter ≥2 mm &lt; 4 mm &gt; 8 mm* Iliac/femoral artery stenosis preclude insertion Paradise Catheter Evidence active infection within 7 day procedure Secondary hypertension include sleep apnea ( documented clinical work within 12 month prior consent see protocol body detail ) Type I diabetes mellitus uncontrolled Type II diabetes ( define plasma Hb1Ac ≥ 9.0 % ) Documented history chronic active inflammatory bowel disorder Chrohn 's disease ulcerative colitis eGFR &lt; 40 mL/min/1.73 m2 ( Modification Diet Renal Disease formula ) Brachial circumference ≥ 42 cm Any history cerebrovascular event ( e.g . stroke , transient ischemic event , cerebrovascular accident ) within 3 month prior consent Any history severe cardiovascular event ( myocardial infarction , CABG , acute heart failure require hospitalization ( NYHA IIIIV ) within 3 month prior consent Documented confirm episode ( ) unstable angina within 3 month prior consent Documented intolerance contraindication antihypertensive drug prescribe requirement study protocol Prescribed standard antihypertensive CV medication ( beta blocker ) chronic condition ( e.g . ischemic heart disease ) discontinuation might pose serious risk health Documented history persistent permanent atrial tachyarrhythmia Active implantable medical device ( e.g . ICD CRTD ; neuromodulator/spinal stimulator ; baroreflex stimulator ) Chronic oxygen support mechanical ventilation nocturnal respiratory support sleep apnea . Primary pulmonary hypertension Documented contraindication allergy contrast medium amenable treatment Limited life expectancy &lt; 1 year discretion Investigator Any known , unresolved history drug use alcohol dependency , lack ability comprehend follow instruction , reason opinion investigator , would unlikely unable comply study protocol requirement whose participation may result data analysis confounders ( e.g . night shift worker ) Pregnant , nurse plan become pregnant ( documented negative pregnancy test require document within maximum 7 day prior procedure woman child bear potential . Documentation effective contraception also required woman child bear potential ) Concurrent enrollment investigational drug device trial ( participation noninterventional Registries acceptable )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>denervation</keyword>
	<keyword>resistant hypertension</keyword>
	<keyword>essential hypertension</keyword>
</DOC>